{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Subject with an event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Event = disease recurrence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Event=death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"82"}]}],"title":"Subjects censored"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"Recurrence-free survival assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event).","groups":[{"description":"All subjects received in tablet form imatinib (STI571) 400 mg once daily.","id":"OG000","title":"Imatinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline up to 60 months","title":"Recurrence-free Survival up to 60 Months","type":"PRIMARY","unitOfMeasure":"participants with an event"}